Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced that Dr. Fahar Merchant, its President and CEO, will speak at the Oppenheimer 33rd Annual Healthcare Conference scheduled for March 14, 2023, at 2:40 PM ET.

Rhea-AI Summary

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced that Dr. Fahar Merchant, its President and CEO, will speak at the Oppenheimer 33rd Annual Healthcare Conference scheduled for March 14, 2023, at 2:40 PM ET. The event will take place virtually from March 13-15, 2023. Attendees can access the live webcast here. Medicenna is a clinical-stage immunotherapy company dedicated to developing innovative cancer treatments, including its lead product MDNA11 and the IL-4 Empowered Superkine, bizaxofusp, which has received FastTrack and Orphan Drug status.

Argus Session date unavailable

+4.64% session move Open Argus

Details

News Market Reaction – MDNA

The recorded move for MDNA in the trading session of this news was +4.64%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TORONTO and HOUSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the Oppenheimer 33^rd Annual Healthcare Conference, which is scheduled to take place virtually from March 13 – 15, 2023.

Details on the fireside chat are as follows:

Oppenheimer 33rd Annual Healthcare Conference
Date:	Tuesday, March 14, 2023
Time:	2:40 PM ET
Webcast:	https://wsw.com/webcast/oppenheimer27/mdna/2750720

Webcast and replay information for this event will be available on the Investor Relations section of Medicenna's website at https://ir.medicenna.com/.

About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Medicenna participate in the Oppenheimer 33rd Annual Healthcare Conference?

Medicenna will participate in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023.

What time is Medicenna's presentation at the Oppenheimer Conference?

Medicenna's presentation is scheduled for 2:40 PM ET on March 14, 2023.

Where can I watch Medicenna's fireside chat?

You can watch Medicenna's fireside chat via the webcast here.

What is MDNA's lead product?

MDNA's lead product is MDNA11, a next-generation IL-2 Superkine.

What status has bizaxofusp received from the FDA?

Bizaxofusp has received FastTrack and Orphan Drug status from the FDA.